Clinical trials
Hidradenitis Suppurativa clinical trials
Below are recruiting hidradenitis suppurativa clinical trials, each written for real people, not researchers. We’re tracking 55 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06058520RecruitingEarly Phase 1
Capsule microbiome transplant for hidradenitis suppurativa
This trial tests whether taking capsules containing healthy gut bacteria (fecal microbiota transplant) can help treat hidradenitis suppurativa. You may qualify if you have HS and haven't taken antibiotics in the last 30 days.
Minneapolis, MinnesotaAges 18 years+ - NCT05507125Recruiting
Study of how inflammatory genes work in hidradenitis
This study looks at how certain body “inflammatory genes” behave in people with hidradenitis suppurativa. It may help researchers understand what drives this condition and how future treatments could be targeted.
Birmingham, AlabamaAges 18–89 - NCT05403710Recruiting
Botox injections for people with hidradenitis suppurativa
This trial studies whether botulinum toxin (Botox) injections can improve hidradenitis suppurativa (HS), a painful skin condition with recurring bumps and tunnels. You might be a good match if you have long-lasting HS in more than one body area and can safely do skin-area treatment visits (including skin biopsy if needed).
Worcester, MassachusettsAges 18–75 - NCT03967600Recruiting
Study of hidradenitis suppurativa skin features
This study looks at the physical and biological (body-related) characteristics of hidradenitis suppurativa. It may help researchers understand the condition better and improve future care.
San Francisco, CaliforniaAges 13 years+ - NCT06895499RecruitingPhase 1/Phase 2
Testing a new drug for hidradenitis suppurativa
This trial tests a new medicine called HB0043 for people with moderate to severe hidradenitis suppurativa (a skin condition causing painful lumps). It aims to see if the drug is safe and helps reduce symptoms.
Jinan, ShandongAges 18 years+ - NCT05821478RecruitingPhase 3
Antibiotics plan for hidradenitis stage 2 flares
This Phase 3 study tests whether an adapted antibiotic treatment works better than the standard approach to control hidradenitis suppurativa (HS) symptoms and flares. It may help people with stage 2 HS reduce active inflammation and flare-ups.
MarseilleAges 18–59 - NCT06707246Recruiting
Comparing secukinumab and tofacitinib for hidradenitis suppurativa
This trial tests two medications, secukinumab and tofacitinib, to see which works better for moderate to severe hidradenitis suppurativa (a skin condition causing painful bumps) in Chinese patients. The goal is to find a more effective treatment option.
Hangzhou, ZhejiangAges 18–75 - NCT04115566Recruiting
HS patient registry and sample storage study
This study enrolls people with hidradenitis suppurativa (HS) to better understand the condition over time and store optional health information and samples. Being in the registry may help researchers learn about patterns in HS and support future research.
San Francisco, CaliforniaAges 10 years+ - NCT06645821RecruitingEarly Phase 1
Cream for mild to moderate hidradenitis suppurativa
This trial tests a new cream (EVO101) for people with mild to moderate hidradenitis suppurativa (HS), a skin condition causing painful lumps. It aims to see if the cream can reduce the number of lesions. Participants cannot use certain other HS treatments during the study.
Norfolk, VirginiaAges 18 years+ - NCT07136467Recruiting
Understanding daily life with vitiligo, alopecia areata, or hidradenitis suppurativa
This study looks at how certain skin conditions affect daily life in teens and adults. Researchers want to understand the challenges people face with vitiligo, alopecia areata, or hidradenitis suppurativa by having participants fill out simple questionnaires.
Ciudad Autonoma de Buenos Aire, Buenos AiresAges 12 years+ - NCT07243782Recruiting
Study of Cosentyx for skin and joint conditions in Korea
This study tracks how well Cosentyx works in real-world use for people with hidradenitis suppurativa, plaque psoriasis, or juvenile idiopathic arthritis. It helps doctors understand the medicine's long-term effects in Korean patients.
Seoul, SeoulAges 6–100 - NCT06785779Recruiting
HS patient satisfaction after starting Cosentyx in Saudi clinics
This study measures how satisfied people with moderate to severe hidradenitis suppurativa (HS) feel with their treatment after starting Cosentyx. It is for adults in Saudi Arabia who have not taken Cosentyx before and are starting it as part of their routine care.
Riyadh, SAUAges 18–99 - NCT06524635RecruitingPhase 2
Study of lutikizumab for hidradenitis suppurativa or eczema
This study tests an investigational medicine called lutikizumab, given as shots under the skin, for people with moderate-to-severe hidradenitis suppurativa (HS) or atopic dermatitis (eczema). It looks at how the medicine affects skin changes and may help if other treatments haven’t worked.
Sacramento, CaliforniaAges 18–75 - NCT07855276RecruitingPhase 1
Study of remibrutinib for moderate to severe hidradenitis suppurativa
This study tests a new oral medication, remibrutinib, in adults with moderate to severe hidradenitis suppurativa (HS), a skin condition causing painful lumps and tunnels. The goal is to see how the drug affects the skin tissue and to gather information for future treatments.
Mayfield Heights, OhioAges 18–65 - NCT07665437RecruitingPhase 3
Long-term safety study of remibrutinib for hidradenitis suppurativa
This study tests the long-term safety and effectiveness of remibrutinib for people with moderate to severe hidradenitis suppurativa (HS) who have already completed a 68-week treatment period in a related study.
Birmingham, AlabamaAges 18–100 - NCT07543419Recruiting
Real-world Study of Secukinumab for Moderate to Severe Hidradenitis Suppurativa
This study tracks how secukinumab (a new medication) works for hidradenitis suppurativa—a painful skin condition with recurring boils and abscesses—in real-world patient care in Italy. Researchers want to understand treatment patterns and outcomes to help improve care for this condition.
Ancona, ANAges 18–100 - NCT07316192Recruiting
Comparing two wound dressings for hidradenitis suppurativa surgery
This study compares two wound dressings used after surgery for hidradenitis suppurativa (HS) to see which one helps wounds heal better. It may help if you need a wide surgical excision for HS and can attend follow-up visits.
Newark, New JerseyAges 18 years+ - NCT07282015Recruiting
Real-world study of secukinumab for HS in Canada
This study looks at how well secukinumab (Cosentyx) works in real life for people with moderate-to-severe hidradenitis suppurativa (HS) in Canada. If you're just starting this treatment, researchers want to track your progress and side effects.
Calgary, AlbertaAges 18–100 - NCT07263230RecruitingPhase 2
Roflumilast Foam for Hidradenitis Suppurativa
This study tests whether roflumilast foam (a prescription foam) is safe and can reduce inflamed bumps in people with mild-to-moderate hidradenitis suppurativa (HS) who do not have draining tunnels. Participants will stop other HS treatments during the trial.
Boston, MassachusettsAges 18 years+ - NCT07123038Recruiting
Long-term safety study for gene-modified Treg therapy recipients
This study follows people who previously received a gene-modified Treg (regulatory T cell) therapy from Sonoma Biotherapeutics. It checks for long-term safety and does not involve any new treatment.
San Francisco, CaliforniaAges 18–71 - NCT07021495Recruiting
Skin disease study to improve treatment choices
This study looks at different skin diseases to find markers that can help guide treatment. It tests new treatments for several conditions like eczema, psoriasis, and lupus, with the goal of personalizing care.
Nijmegen, GelderlandAges 18 years+ - NCT06993233RecruitingPhase 2
Study of CIT-013 for hidradenitis suppurativa
This trial tests a new medication called CIT-013 for people with moderate to severe hidradenitis suppurativa (HS) who have not had enough relief from oral antibiotics. The goal is to see if this treatment can reduce painful bumps and abscesses.
BarrieAges 18 years+ - NCT06946641RecruitingPhase 1
Testing QLS12010 safety in healthy adults and people with eczema
This trial tests a new drug, QLS12010, to see if it is safe and how it works in healthy volunteers and in people with moderate to severe atopic dermatitis (eczema). It may offer a new treatment option for those whose eczema has not improved with topical creams.
BeijingAges 18–75 - NCT06888193RecruitingPhase 1
Bimekizumab in breast milk of mothers being treated
This study measures how much bimekizumab (Bimzelx) gets into breast milk. It helps us understand if the medicine is safe for breastfeeding babies whose mothers take this drug.
Santa Monica, CaliforniaAges 18 years+
Hear when a new Hidradenitis Suppurativa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hidradenitis suppurativa?
- Yes. Clin2 currently lists 55 recruiting hidradenitis suppurativa studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hidradenitis suppurativa trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hidradenitis suppurativa trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.